Skip to main content
Graduate School of Biomedical Sciences

Recent Publications from the Covic Lab

Rana R, Shearer AM, Fletcher EK, Nguyen N, Guha S, Cox DH, Abdelmalek M, Wang Y, Baleja JD, Covic L, Kuliopulos A. 2019. PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. Mol Metab. 29:99-113. Abstract

Kimmelstiel C, Stevenson R, Nguyen N, Van Doren L, Zhang P, Perkins J, Kapur NK, Weintraub A, Castaneda V, Kuliopulos A, Covic L. 2019. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel. Thromb Res. 177: 59-69. Abstract

Michael ES, Covic L, Kuliopulos A. 2019. TAAR1 promotes anti-diabetic signaling in insulin-secreting cells. J Biol Chem. Epub ahead of print.  Abstract

Barr TP, Garzia C, Guha S, Fletcher EK, Nguyen N, Wieschhaus AJ, Ferrer L, Covic L, Kuliopulos A. 2018. PAR2 pepducin-based suppression of inflammation and itch in atopic dermatitis models. J Invest Dermatol. Epub ahead of print. Abstract

Covic L, Kuliopulos A. 2018. Protease-activated receptor 1 as therapeutic target in breast, lung, and ovarian cancer: Pepducin approach. Int J Mol Sci. 19: E2237. Abstract

Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A, Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos A. 2018. Noncanonical matrix metalloprotease 1-protease-activated receptor 1 signaling drives progression of atherosclerosis. Arterioscler Thromb Vasc Biol. Eupb ahead of print. Abstract

Shearer AM, Rana R, Austin K, Baleja JD, Nguyen N, Bohm A, Covic L, Kuliopulos A. 2016. Targeting liver fibrosis with a cell-penetrating PAR2 pepducin. J Biol Chem. 291: 23188-23198. Abstract

Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A. 2015. Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease. Arterioscler Thromb Vasc Biol. 36: 189-197.  Abstract

Zhang P, Covic L, Kuliopulos A. 2015. Pepducins and other lipidated peptides as mechanistic probes and therapeutics. Methods Mol Biol. 1324: 191-203.  Abstract

Yang E, Cisowski J, Nguyen N, O'Callaghan K, Xu J, Agarwal A, Kuliopulos A, Covic L. 2015. Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. Oncogene. 35: 1529-1540. Abstract

Zhang P, Leger AJ, Baleja JD, Rana R, Corlin T, Nguyen N, Koukos G, Bohm A, Covic L, Kuliopulos A. 2015. Allosteric activation of a G protein coupled receptor with cell-penetrating receptor mimetics. J Biol Chem. 290: 15785-15798. Abstract

Austin KM, Nguyen N, Javid G, Covic L, Kuliopulos A. 2013. Non-canonical MMP1-PAR1 signaling triggers vascular smooth muscle cell de-differentiation and arterial stenosis. J Biol Chem. 288: 23105-23115. Abstract

Foley CJ, Fanjul-Fernández M, Bohm A, Nguyen N, Agarwal A, Austin K, Koukos G, Covic L, López-Otín C, Kuliopulos A. 2013. Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis. Oncogene 33: 2264-2272. Abstract

Michael ES, Kuliopulos A, Covic L, Steer ML, Perides G. 2013. Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute experimental biliary pancreatitis. Am J Physiol Gastrointest Liver Physiol. 304: G516-G526. Abstract

Kaimal R, Aljumaily R, Tressel SL, Pradhan RV, Covic L, Kuliopulos A, Zarwan C, Kim YB, Sharifi S, Agarwal A. 2013. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis and tumor growth in ovarian cancer. Cancer Res. 73: 2457-2467. Abstract

Austin KM, Covic L, Kuliopulos A. 2013. Matrix metalloproteases and PAR1 activation. Blood. 121: 431-439. Abstract

Zhang P, Gruber A, Kasuda S, Kimmelstiel C, O'Callaghan K, Cox DH, Bohm A, Baleja JD, Covic L, Kuliopulos A. 2012. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 126: 83091. Abstract

O'Callaghan K, Kuliopulos A, Covic L. 2012. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem. 287: 12787-12796.Abstract

Foley CJ, Luo C, O’Callaghan K, Hinds P, Covic L, Kuliopulos A. 2012. Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J Biol Chem. 287: 24330-24338.  Abstract

O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L. 2012. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 11: 1717-1725. Abstract

Sevigny LM, Austin KM, Zhang P, Kasuda S, Koukos G, Sharifi S, Covic L, Kuliopulos A. Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler Thromb Vasc Biol. 31: e100-106. Abstract

Dimond P, Carlson K, Bouvier M, Gerard C, Xu L, Covic L, Agarwal A, Ernst OP, Janz JM, Schwartz TW, Gardella TJ, Milligan G, Kuliopulos A, Sakmar TP, Hunt SW 3rd. 2011. G protein-coupled receptor modulation with pepducins: moving closer to the clinic. Ann NY Acad Sci. 1226: 34-49. Abstract

Tressel SL, Kaneider NC, Kasuda S, Foley C, Koukos G, Austin K, Agarwal A, Covic L, Opal SM, Kuliopulos A. 2011. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 3: 370-384. Abstract

Sevigny LM, Zhang P, Bohm A, Lazarides K, Perides G, Covic L, Kuliopulos A. 2011. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci USA 108: 8491-8496. Abstract

Cisowski J, O’Callaghan K, Kuliopulos A, Yang J, Nguyen N, Deng Q, Yang E, Fogel M, Tressel S, Foley C, Agarwal A, Hunt III SW, McMurry T, Brinckerhoff L, Covic L. 2011. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Amer J Pathol.  179: 513-523. Abstract

Kimmelstiel C, Zhang P, Kapur NK, Weintraub A, Krishnamurthy B, Castaneda V, Covic L, Kuliopulos A. 2011. Bivalirudin Is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 1: 171-179. Abstract

Dowal L, Sim DS, Dilks JR, Blair P, Beaudry S, Denker BM, Koukos G, Kuliopulos A, Flaumenhaft R. 2011.  Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc Natl Acad Sci USA 108: 2951-2956.  Abstract

Koukos G, Sevigny L, Zhang P, Covic L, Kuliopulos A. 2011. Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury. IUBMB Life 63: 412-418. Abstract